This paper explores the adoption of redistributed manufacturing strategies by UK pharmaceutical firms. A multiple case study of six firms is coupled with expert opinion from academics in the fields of innovation, life sciences, pharmaceuticals and additive manufacturing. A triangulated data collection strategy is used including twenty-five semi-structured interviews, eight focus groups and primary documentation. Drawing on adoption theory we identify the enablers of and barriers to the adoption of redistributed manufacturing strategies. The findings suggest that redistributed manufacturing will not replace existing supply chain configurations but instead complement them. Several potential niche applications for redistributed manufacturing are identifie
